|
Molecular properties generated using the CDK |
Classification ![]() |
|
| Compound class | Synthetic organic |
| Approved drug? | Yes (source: UK (1993)) |
IUPAC Name ![]() |
| N-[1-[2-(1H-indol-3-yl)ethyl]piperidin-4-yl]benzamide |
International Nonproprietary Names ![]() |
|
| INN number | INN |
| 3064 | indoramin |
Synonyms ![]() |
| Baratol® |
| Doralese® |
| indoramine |
| WY-21901 |
Database Links ![]() |
|
| BindingDB Ligand | 50033113 |
| CAS Registry No. | 26844-12-2 (source: Scifinder) |
| ChEMBL Ligand | CHEMBL279516 |
| PubChem CID | 33625 |
| Search Google for chemical match using the InChIKey | JXZZEXZZKAWDSP-UHFFFAOYSA-N |
| Search Google for chemicals with the same backbone | JXZZEXZZKAWDSP |
| Search PubMed clinical trials | indoramin |
| Search PubMed titles | indoramin |
| Search PubMed titles/abstracts | indoramin |
| Wikipedia | Indoramin |
| Comments |
| Indoramin is a selective antagonist of α1-adrenoceptors [3]. |